A Randomized Clinical Trial Comparing 2 Levothyroxine Regimens During Ramadan Fasting in Thyroidectomized Patients.

IF 3 Q2 ENDOCRINOLOGY & METABOLISM Journal of the Endocrine Society Pub Date : 2024-10-09 eCollection Date: 2024-09-26 DOI:10.1210/jendso/bvae173
Ali S Alzahrani, Noha Mukhtar, Zahrah Alhammad, Lulu Alobaid, Abdulrhman Jaber Hakami, Osamah Alsagheir, Gamal Mohamed, Maha Hameed, Abdulraof Almahfouz
{"title":"A Randomized Clinical Trial Comparing 2 Levothyroxine Regimens During Ramadan Fasting in Thyroidectomized Patients.","authors":"Ali S Alzahrani, Noha Mukhtar, Zahrah Alhammad, Lulu Alobaid, Abdulrhman Jaber Hakami, Osamah Alsagheir, Gamal Mohamed, Maha Hameed, Abdulraof Almahfouz","doi":"10.1210/jendso/bvae173","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>For Muslim patients on levothyroxine (L-T4) therapy, the best approach for L-T4 intake during Ramadan fasting remains unclear.</p><p><strong>Objective: </strong>We compared 2 practical approaches for L-T4 intake during Ramadan.</p><p><strong>Methods: </strong>We randomly assigned 69 patients (21 males, 48 females, median age 44 years) with differentiated thyroid cancer (DTC) who underwent thyroidectomy in the past and are on stable LT4 doses to 2 arms. Arm A (33 patients) ingested their pre-Ramadan L-T4 dose at the evening meal and ate immediately. Arm B (36 patients) increased their pre-Ramadan dose by 25 µg if their regular L-T4 dose was ≤150 µg/day or by 50 µg if their pre-Ramadan dose was >150 µg/day and ate immediately.</p><p><strong>Results: </strong>At the beginning of Ramadan (baseline), the median thyrotropin (TSH) level and the numbers of patients in euthyroidism, subclinical hyperthyroidism (Shyper), or subclinical hypothyroidism (Shypo) were comparable between the 2 arms (<i>P</i> = .69 and <i>P</i> = .65, respectively). At the end of Ramadan, in arm A there were 17 (51.5%), 3 (9.1%), and 13 (39.4%) patients in euthyroidism, Shyper, and Shypo compared with 17 (47.2%), 14 (38.9%), and 5 (13.9%) patients, respectively, in arm B (<i>P</i> = .005). The mean ± SD TSH levels in arms A and B at the end of Ramadan were 5.6 ± 6.0 mU/L and 1.67 ± 2.6 mU/L, respectively (<i>P</i> = .0001).</p><p><strong>Conclusion: </strong>No overt thyroid dysfunction developed but there were more cases of Shypo in arm A and Shyper in arm B. Arm B achieved desirable levels of TSH (normal or slightly suppressed) in 86% of cases and might be a preferable approach, especially for patients who need TSH suppression (eg, DTC).</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 11","pages":"bvae173"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497607/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Endocrine Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jendso/bvae173","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/26 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Context: For Muslim patients on levothyroxine (L-T4) therapy, the best approach for L-T4 intake during Ramadan fasting remains unclear.

Objective: We compared 2 practical approaches for L-T4 intake during Ramadan.

Methods: We randomly assigned 69 patients (21 males, 48 females, median age 44 years) with differentiated thyroid cancer (DTC) who underwent thyroidectomy in the past and are on stable LT4 doses to 2 arms. Arm A (33 patients) ingested their pre-Ramadan L-T4 dose at the evening meal and ate immediately. Arm B (36 patients) increased their pre-Ramadan dose by 25 µg if their regular L-T4 dose was ≤150 µg/day or by 50 µg if their pre-Ramadan dose was >150 µg/day and ate immediately.

Results: At the beginning of Ramadan (baseline), the median thyrotropin (TSH) level and the numbers of patients in euthyroidism, subclinical hyperthyroidism (Shyper), or subclinical hypothyroidism (Shypo) were comparable between the 2 arms (P = .69 and P = .65, respectively). At the end of Ramadan, in arm A there were 17 (51.5%), 3 (9.1%), and 13 (39.4%) patients in euthyroidism, Shyper, and Shypo compared with 17 (47.2%), 14 (38.9%), and 5 (13.9%) patients, respectively, in arm B (P = .005). The mean ± SD TSH levels in arms A and B at the end of Ramadan were 5.6 ± 6.0 mU/L and 1.67 ± 2.6 mU/L, respectively (P = .0001).

Conclusion: No overt thyroid dysfunction developed but there were more cases of Shypo in arm A and Shyper in arm B. Arm B achieved desirable levels of TSH (normal or slightly suppressed) in 86% of cases and might be a preferable approach, especially for patients who need TSH suppression (eg, DTC).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
比较甲状腺切除术患者在斋月禁食期间使用两种左旋甲状腺素治疗方案的随机临床试验
背景:对于接受左甲状腺素(L-T4)治疗的穆斯林患者来说,在斋月禁食期间摄入 L-T4 的最佳方法仍不明确:我们比较了斋月期间摄入 L-T4 的两种实用方法:我们将 69 名既往接受过甲状腺切除术、LT4 剂量稳定的分化型甲状腺癌(DTC)患者(21 名男性,48 名女性,中位年龄 44 岁)随机分配到两组。A组(33名患者)在晚饭时摄入拉马丹治疗前的L-T4剂量,并立即进食。B组(36名患者)如果他们的常规L-T4剂量≤150微克/天,则将斋月前的剂量增加25微克;如果斋月前的剂量>150微克/天,则增加50微克,并立即进食:斋月开始时(基线),两组患者的促甲状腺激素(TSH)中位数水平以及甲状腺功能亢进、亚临床甲状腺功能亢进(Shyper)或亚临床甲状腺功能减退(Shypo)的人数相当(P = .69 和 P = .65)。斋月结束时,A 组患者中分别有 17 人(51.5%)、3 人(9.1%)和 13 人(39.4%)处于甲状腺功能亢进、Shyper 和 Shypo 状态,而 B 组患者中分别有 17 人(47.2%)、14 人(38.9%)和 5 人(13.9%)处于上述状态(P = .005)。斋月结束时,A组和B组的平均±标清TSH水平分别为5.6±6.0 mU/L和1.67±2.6 mU/L(P = .0001):B组有86%的病例达到了理想的促甲状腺激素水平(正常或轻微抑制),可能是一种更可取的方法,尤其是对于需要抑制促甲状腺激素的患者(如DTC)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of the Endocrine Society
Journal of the Endocrine Society Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
5.50
自引率
0.00%
发文量
2039
审稿时长
9 weeks
期刊最新文献
A Stronger IMPACT on Career Development for Early- and Mid-career Faculty. Blood Pressure Decreases in Overweight Elderly Individuals on Vitamin D: A Randomized Trial. Aromatase Inhibitor Monotherapy to Augment Height in Boys: Does It Work and Is It Safe? Innovative Glucagon-based Therapies for Obesity. Efficacy of Tocilizumab in Refractory Graves Orbitopathy From Real-World Clinical Practice: An Observational Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1